#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
CS

Hyperuricemia and kidney

Czech version

Authors: Viera Spustová 1;  Andrej Dukát 2
Authors‘ workplace: Ústav farmakológie a klinickej farmakológie – Oddelenie klinickej a experimentálnej farmakoterapie LF SZU v Bratislave 1;  V. interná klinika LF UK a UNB, Nemocnica Ružinov, Bratislava 2
Published in: Forum Diab 2019; 8(1): 26-28

Overview

For a certain time it was known about the relationship between acid uric level and cardiorenal syndrome, but only recently new causalities were shown in the field of pathophysiology and clinics.

Nowadays there is confirmed the role of hyperuricaemia realted renal dysfunction. In this paper, the authors bring the summary of these relationships.

Keywords:

acid uric – cardiorenal syndrome – hyperuricemia

Sources
  1. Borghi C, Tykaeski A, Widecka K et al. Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk. Cardiol J 2018; 25(5): 545–563. Dostupné z DOI: <http://dx.doi.org/10.5603/CJ.2018.0116>.
  2. Giordano C, Karasik O, King-Morris K et al. Uric acid as a Marker of Kidney Disease: Review of the Current Literature. Dis Markers 2015; 2015: 382918: Dostupné z DOI: <http://dx.doi.org/10.1155/2015/382918>.
  3. Siu YP, Leung KT, Tong MK et al. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 2006; 47(1): 51–59. Dostupné z DOI: <http://dx.doi.org/10.1053/j.ajkd.2005.10.006>.
  4. Roncal Jimenez CA, Ishimoto T, Lanaspa MAet al. Fructokinase activity media-tes dehydration-induced renal injury. Kidney Int 2014; 86(2): 294–302. Dostupné z DOI: <http://dx.doi.org/10.1038/ki.2013.492>.
  5. Chonchol M, Shlipak MG, Katz R et al. Relationship of uric acid with progres-sion of kidney disease. Am J Kidney Dis 2007; 50(2): 239–247. Dostupné z DOI: <http://dx.doi.org/10.1053/j.ajkd.2007.05.013>.
  6. Iseki K, Oshiro S, Tozawa M et al. Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects. Hypertens Res 2001; 24(6): 691–697.
  7. Weiner DE, Tighiouart H, Elsayed EF et al. Uric acid and incident kidney disease in the community. J Am Soc Nephrol 2008; 19(6): 1204–1211. Dostupné z DOI: <http://dx.doi.org/10.1681/ASN.2007101075>.
  8. Odden MC, Amadu AR, Smit E et al. Uric acid levels, kidney function and cardiovascular mortality in US adults: national health and nutrition examination survey 1988–1994 and 1999–2002. Am J Kidney Dis 2014; 64(4): 550–557. Dostupné z DOI: <http://dx.doi.org/10.1053/j.ajkd.2014.04.024>.
  9. Weiner DE, Tighiouart H, Elsayed EF et al. The relationship between non-traditional risk factors and outcomes in individuals with stage 3–4 CKD. Am J Kidney Dis 2008; 51(2): 212–223. Dostupné z DOI: <http://dx.doi.org/10.1053/j.ajkd.2007.10.035>.
  10. Suliman ME, Johnson RJ, García-López E et al. J-shaped mortality rela-tionship for uric acid in CKD. Am J Kidney Dis 2006; 48(5): 761–771. Dostupné z DOI: <http://dx.doi.org/10.1053/j.ajkd.2006.08.019>.
  11. Goicoechea M1, de Vinuesa SG, Verdalles U et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 2010; 5(8): 1388–1393. Dostupné z DOI: <http://dx.doi.org/10.2215/CJN.01580210>.
  12. George J, Carr E, Davies J et al. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation 2006; 114(23): 2508–2516. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.106.651117>.
  13. Ejaz AA, Dass B, Lingegowda V et al. Effect of uric acid lowering therapy on the prevention of acute kidney injury in cardiovascular surgery. Int Urol Nephrol 2013; 45(2): 449–458. Dostupné z DOI: <http://dx.doi.org/10.1007/s11255–012–0192–2>.
  14. Høieggen A, Alderman MH, Kjeldsen SE et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004; 65(3): 1041–1049. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1523–1755.2004.00484.x>.
  15. Management of progression and complications of CKD. In: KDIGO 2012 practice guidelines for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013; 3(1): 73–90. Dostupné z DOI: <http://doi:10.1038/kisup.2012.66>.
  16. Lapsia V, Johnson RJ, Dass B et al. Elevated uric acid increases the risk for acute kidney injury. Am J Med 2012; 125(3): 302.e9–e17. Dostupné z DOI: <http://dx.doi.org/10.1016/j.amjmed.2011.06.021>.
  17. Giordano C, Karasik O, King-Morris K et al. Uric Acid as a Marker of Kidney Disease. Dis Markers 2015; 2015: 382918. Dostupné z DOI: <http://dx.doi.org/10.1155/2015/382918>.
Labels
Diabetology Endocrinology Internal medicine
Uric acid: pathophysiological implications
Hyperuricemia and cardiovascular diseases
Hyperuricemia and diabetes mellitus
Gout as a new old problem faced by an outpatient care physician
Treatment of hyperuricemia
Treat to target in gouty arthritis
Article was published in

Forum Diabetologicum

Issue 1
2019 Issue 1
Most read in this issue
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#